BioSpace News Archive

Bristol-Myers Squibb Company announced data from the phase 2 CA180-372 study in pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with Sprycel (dasatinib) added to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone.

These data include longer-term results from the pivotal HAVEN 1 and HAVEN 2 studies in people with hemophilia A with inhibitors to factor VIII, showing once-weekly subcutaneous HEMLIBRA prophylaxis demonstrated superior efficacy compared to prior treatment with bypassing agents (BPAs) as prophylaxis or on-demand.

The studies employ unique therapeutic approaches and advanced engineering technologies such as the gene-editing platform CRISPR/Cas9, reflecting the fruits of many years of research dedication and innovation.

Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder.

The pooled analysis also found that patients who were treated with ibrutinib earlier, after their first relapse/progression, experienced higher rates of OS and PFS.

The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability.

Tetra Bio-Pharma announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process.

The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta and demonstrate the safety profile and efficacy of CALQUENCE in the management of previously-treated mantle cell lymphoma (MCL).

Abatacept, when added to the standard drug regimen used to prevent GvHD, reduced the occurrence of acute, grade III-IV GvHD from 32 to 3 percent in pediatric and adult patients who underwent mismatched unrelated donor stem cell transplants to treat advanced cancer and other blood disorders.

Juno Therapeutics today presented new translational insights on clinical outcomes with its investigational CAR T product candidate JCAR017 at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.